The lipid-modifying efficacy and safety of once-daily ezetimibe 10 mg have been established in phase III clinical trials, in which ezetimibe has been investigated as monotherapy, as an add-on to ongoing statin therapy, and as combination therapy with statins in patients with primary hypercholesterolemia, including patients with coronary heart disease (CHD), diabetes, or two or more risk factors for CHD. The effect of ezetimibe on the absorption of cholesterol, plant sterols, and blood levels of lipid-soluble vitamins has also been examined, as well as potential drug-drug interactions when ezetimibe is co-administered with other lipid-altering agents. Finally, ezetimibe has been studied in patients with homozygous familial hypercholesterolemia and in patients with sitosterolemia.
In this study, treatment with ezetimibe also significantly reduced plasma concentrations of the plant sterols sitosterol and campesterol by 41% and 48%, respectively, compared with placebo ( P <0·001). Similar results were observed for the ratios of these sterols to cholesterol. These findings strongly suggest that ezetimibe inhibits the absorption of both cholesterol and plant sterols [1] , an effect that has important implications for patients with sitosterolemia, as described later [2] .
Additionally, in a large phase III clinical trial, the impact of ezetimibe treatment on the plasma concentrations of lipid-soluble vitamins (carotenoids and vitamins A, D, and E) was evaluated. Administration of ezetimibe did not alter the serum concentrations of any of the lipid-soluble vitamins nor have a significant effect on prothrombin time (a surrogate for vitamin K activity) [3] .
Drug-drug interactions
Phase I studies demonstrated that ezetimibe 10 mg did not have any clinically significant drug-drug interactions when co-administered with lovastatin [4] , cimetidine [5] , digoxin [6] , glipizide [7] , oral contraceptives (norgestrel plus ethinyl estradiol) [8] , warfarin [9] , atorvastatin [10] , simvastatin [11] , fluvastatin [12] , or fenofibrate [13] . In a Phase I pharmacokinetic study, cholestyramine was shown to reduce the systemic plasma concentration of ezetimibe by approximately 55% (data on file). Table 1 lists the drug-drug interaction studies with ezetimibe reported to date.
Ezetimibe monotherapy studies
Two large companion phase III studies evaluated the efficacy and safety of ezetimibe 10 mg monotherapy in patients with mild to moderate primary hypercholesterolemia (lowdensity lipoprotein cholesterol [LDL-C] 130-250 mg .dl -1 , triglycerides [TG] ≤ 350 mg .dl -1 ) [14, 15] .I n these multicenter, double-blind trials, patients were randomized in a 3:1 ratio to ezetimibe 10 mg or matching placebo in the morning for 12 weeks; Study 1 enrolled 892 patients (666 on ezetimibe, 226 on placebo) [14] , and Study 2 enrolled 827 patients (622 on ezetimibe, 205 on placebo) [15] . At the time of this writing, Study 1 has been published as a full manuscript and Study 2 as an abstract. While the results of the two studies were similar, most of the data presented here are from Study 1 [14] .
Efficacy results
Mean baseline LDL-C levels were approximately 168mg.dl -1 in Study 1 [14] and 164 mg .dl -1 in Study 2 [15] . Compared with placebo, directly measured LDL-C was 17·3% lower with ezetimibe in Study 1 and 18·5% lower in Study 2. In both studies, the effects of ezetimibe on LDL-C occurred within 2weeks and persisted throughout the 12-week treatment period. The response to ezetimibe was generally consistent across all subgroups, regardless of risk factor status, gender, age, race, or baseline lipid profiles [14, 15] . In Study 1, compared with placebo, ezetimibe treatment also had significant beneficial effects on mean percentage changes in other lipid-related variables, including total cholesterol, high-density lipoprotein cholesterol (HDL-C; increased 2·9%), and TG (reduced 11·4%). In Study 2, similar benefit was observed on HDL-C (increased 2·3%), but with a more modest change in TG (reduced 4·1%) (see Table 2 ).
Safety results
In Study 1 [14] , the adverse event (AE) profiles for the ezetimibe and placebo groups were similar. Most of the AEs (approximately 95% of those reported in both studies) were judged by the investigator to be mild or moderate at their greatest intensity. Table 3 lists the most commonly reported AEs. Overall, a similar percentage of patients reported AEs in the ezetimibe group than in the placebo group (63% versus 66%). The nature, number, and pattern of occurrences of AEs that led to study discontinuation
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Impact of intake of cholesterol and fat
Pooled data on dietary intake from these two studies were used t o assess the effect of dietary saturated fat and cholesterol restriction on the efficacy of treatment with ezetimibe. Participants in the studies were given dietary counseling on the use of the National Cholesterol Education Program (NCEP)
Step I or stricter low-fat, low-cholesterol diet, and compliance with the diet was assessed every 2 to 6weeks during the treatment period at a centralized location by computer analysis of 3-day food-intake records.
In an analysis using a Ratio of Ingested Saturated Fat and Cholesterol to Calories (RISCC) score to quantify all fatrelated diet components and to compare diets between treatments, mean percentage change in directly measured plasma LDL-C from baseline to final assessment was similar for the first (lowest) and fourth (highest) quartiles of RISCC values among both ezetimibe (16% and 19% for the respective quartiles) and placebo (0·5% and 1·0% for the respective quartiles) patients, suggesting that the efficacy of ezetimibe in reducing LDL-C is essentially unaffected by the intake of cholesterol and fat [16] .
Conclusions from monotherapy studies
The results of these two studies were consistent and established the efficacy and safety of ezetimibe 10 mg once daily as monotherapy for patients with primary hypercholesterolemia. Ezetimibe 10 mg monotherapy for 12 weeks led to significant reductions in the levels of LDL-C, total cholesterol, and TG (Study 1), and to significant increases in the levels of HDL-C. Ezetimibe was well tolerated and overall, there was no evidence of any clinically meaningful differences between the AE profiles of ezetimibe and placebo [14, 15] .
Ezetimibe and statin combination therapy studies
Statins are the most commonly prescribed cholesterolaltering agents. However, despite the impressive reductions in LDL-C that can be attained using statins, a substantial percentage of patients require additional LDL-C reduction [14] Study 2 [15] Placebo Ezetimibe Placebo Ezetimibe Va riable (n = 226) (n = 666) P value (n = 205) (n = 622) P value
Not reported in abstract; 2 data on file; NS=not significant. beyond that obtained with current statin regimens to achieve target levels recommended by NCEP [17] . Combination therapy with statins and other currently available lipidaltering agents (fibric acid derivatives, bile acid sequestrants, and niacin) may offer an advantage over statin monotherapy, in that potentially more patients could achieve target levels. However, combination therapy with these agents can be limited by an increased risk for side effects, intolerance, noncompliance, and drug interactions [17] . Ezetimibe inhibits absorption of biliary and ingested cholesterol in the intestine, resulting in a reduction in cholesterol that is taken up by the liver. The mechanism of action of ezetimibe is complementary to that of statins, which inhibit cholesterol synthesis in the liver; therefore, using both agents could produce additive effects on LDL-C reduction [1, 18] . Also, the addition of ezetimibe 10 mg to a low dose of a statin can avoid the risk for potentially serious AEs associated with the use of a high dose of a statin.
Add-on therapy
Design and objectives of the study The efficacy and safety of adding ezetimibe to ongoing statin monotherapy was evaluated in 769 patients with primary hypercholesterolemia, many of whom had CHD and/or diabetes mellitus or multiple CHD risk factors, and all of whom required further LDL-C lowering than they had obtained on statin monotherapy [18] . All patients had been on a stable dose of statins for a minimum of 6weeks before being randomized 1:1 to ezetimibe 10 mg once daily (n =379) or placebo (n =390) in addition to continuing their open-label statin for 8weeks. Of these patients, 521 (67·8%) had established CHD and/or diabetes mellitus; 174 (22·6%) had no CHD but had two or more CHD risk factors; and 74 (9·6%) had no CHD and less than two risk factors. At baseline, 308 patients (40%) were taking atorvastatin, 240 (31%) were taking simvastatin, and 221 (29%) were taking another statin (pravastatin, fluvastatin, cerivastatin, or lovastatin). All the statins were used across their full dose ranges [18] .
Efficacy results
The mean calculated LDL-C level at baseline (statin monotherapy before the addition of ezetimibe) was approximately 138 mg .dl -1 . For the primary efficacy variable of mean percentage change in calculated LDL-C from baseline to final assessment after the addition of the study drug, statin plus ezetimibe patients had an additional 21·4% reduction compared with statin plus placebo patients (25·1% vs 3·7%, P <0·001) (Fig. 1a) . Near-maximal lowering of LDL-C was observed at 2weeks and was maintained throughout the 8-week treatment period. The addition of ezetimibe to ongoing statin therapy further reduced LDL-C to similar degrees regardless of the statin used, and across a variety of patient subgroups (Fig. 2) . Among patients not at NCEP LDL-C goal at baseline, 71·5% receiving statin plus ezetimibe reached their goal at final assessment compared with only 18·9% receiving statin plus placebo ( P <0·001) [18] (Fig. 1b) .
Among the secondary efficacy variables, HDL-C was increased by an additional 1·7% with statin plus ezetimibe than with statin plus placebo (2·7% vs 1·0%, P <0·05), and TG was reduced by an additional 11·1% (14·0% vs 2·9%, P <0·001) (Fig. 1a) [18] .
Safety results
Statin plus ezetimibe therapy was well tolerated and had a safety profile similar to that of statin plus placebo. Approximately 95% of patients in each study arm completed treatment, and no pattern or trend was detected to suggest any difference in the distribution of reasons for discontinuation between the treatment groups. Gastrointestinal (GI) system disorder was the most common AE leading to discontinuation, occurring in five patients (1%) in each arm of the study. Overall, 4% of the patients in both treatment groups discontinued treatment because of an AE.
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Elevations in either ALT or AST ≥ 3×ULN at two consecutive postbaseline measurements were similar in the two treatment groups, occurring in 1% of statin plus ezetimibe recipients (n =4, 3 of whom had ALT and/or AST values above ULN prior to treatment), and <1% of statin plus placebo recipients (n =1). In all five patients, levels returned to normal range after discontinuation of treatment [18] .
No case of rhabdomyolysis was reported in either treatment group. One patient, receiving cerivastatin plus placebo, had consecutive CK elevations ≥ 10 ×ULN and muscle pain consistent with myopathy. During the course of this study, cerivastatin was withdrawn from the market. No other patient had CK ≥ 10 ×ULN with or without associated muscle symptoms [18] .
Results of additional measures of safety revealed no evidence of any difference in incidence of other AEs with ezetimibe treatment compared with placebo [18] .
Conclusions from add-on therapy study
Addition of ezetimibe to ongoing statin therapy led to substantial additional improvements in LDL-C, HDL-C, TG, and apo B and facilitated attainment of NCEP LDL-C goals in high-risk patients. The safety profile of ezetimibe plus statin was similar to that of statin plus placebo. The addition of ezetimibe to ongoing statin therapy offers a potential new therapeutic option for patients r eceiving statins who require further LDL-C reductions to achieve recommended targets.
Co-administration studies
Four phase III studies of equivalent size and design evaluated the efficacy and safety of ezetimibe 10 mg once daily coadministered with simvastatin (n =668), atorvastatin (n =628), pravastatin (n =538), or lovastatin (n =548) in patients with primary hypercholesterolemia (LDL-C 145-250 mg .dl -1 , plasma TG ≤ 350 mg .dl -1 ) [19] [20] [21] [22] [23] .I n these multicenter, double-blind, parallel-group studies, patients were randomized to receive 1 of either 8 or 10 treatments administered once daily for 12 weeks: ezetimibe 10 mg monotherapy; statin monotherapy dosed at 10 mg, 20 mg, 40 mg, or 80 mg for simvastatin [20] and atorvastatin [21] and 10 mg, 20 mg, or 40 mg for pravastatin [22] and lovastatin [23] ; ezetimibe 10 mg plus statin at each of the above doses; or placebo (Fig. 3) . In each of these studies, the primary efficacy variable was the percentage change from baseline in directly measured LDL-C (beta quantification), comparing statin alone (pooled across all doses) with ezetimibe 10 mg plus statin (pooled across all doses). Secondary efficacy endpoints included percent change from baseline for calculated LDL-C, HDL-C, and TG.
Efficacy results for all four studies are summarized in Table 4 . The co-administration of ezetimibe 10 mg with statin (pooled doses) provided an additional significant reduction in LDL-C compared with statin monotherapy (pooled doses) regardless of statin type. The incremental reductions from baseline in LDL-C observed for ezetimibe co-administered with simvastatin, atorvastatin, pravastatin, and lovastatin were 13·8%, 12·1%, 13·4%, and 14·3%, respectively (all significant at P <0.01 compared with statin monotherapy). The difference in incremental LDL-C reduction observed in these trials versus the study in which ezetimibe was added on to statin therapy can be attributed to the method by which one calculates the incremental change in LDL-C; change in LDL-C/baseline LDL-C level on no therapy versus change in LDL-C/LDL-C level on statin therapy. I n the co-administration studies, the average incremental LDL-C reduction achieved by combination of ezetimibe plus statin compared with the LDL-C level achieved by statin monotherapy was on average 21% (18% to 24% depending on the statin; data on file), which is the same benefit as seen in the add-on study. Depending on the statin dose, LDL-C-lowering with ezetimibe + statin ranged from -44% to -57% for simvastatin (10-80 mg), -50% to -60% for atorvastatin (10-80 mg), -34% to -41% for pravastatin (10-40 mg), and -33% to -45% for lovastatin (10- [20] n = 70 n = 61 n = 263 n = 274
Atorvastatin [21] n = 60 n = 65 n = 248 n = 255
Pravastatin [22] n = 65 n = 64 n = 205 n = 204
Lovastatin [23] n = 64 n = 72 n = 220 n = 192
*Ezetimibe 10 mg + pooled statin versus pooled statin.
or atorvastatin as with 80 mg of simvastatin or atorvastatin (Fig. 4 ) [20] [21] [22] [23] .
Compared with statin monotherapy, ezetimibe plus statin treatment also produced incremental reductions in plasma levels of TG (7·5%, 8·0%, 10%, and 10·5% for simvastatin, atorvastatin, pravastatin, and lovastatin, respectively; P <0·01 for all statins). With the exception of pravastatin, significant incremental increases in HDL-C were also observed with the co-administration of ezetimibe plus statins compared with statin monotherapy [20] [21] [22] [23] .
In a separate analysis, efficacy data from all four studies were pooled to evaluate the consistency of the lipid profile effects of ezetimibe across various patient subgroups. The results of this analysis showed that ezetimibe produced beneficial effects on LDL-C, total cholesterol, TG and HDL-C in subgroups of patients defined by age (< 65 and ≥ 65 years), gender, and diagnosis of diabetes mellitus or established CHD [24] .
In all four studies, ezetimibe was well tolerated and no clinically meaningful differences between the ezetimibe plus statin and statin alone groups were observed in terms of AEs or discontinuations due to AEs. Ezetimibe plus statin had a safety profile similar to statin monotherapy.
Conclusions from statin co-administration studies
When co-administered with simvastatin, atorvastatin, pravastatin, or lovastatin, ezetimibe consistently provided incremental favorable effects on the lipid profile (LDL-C, TG, HDL-C, total cholesterol); except for the HDL-C effect with pravastatin, these effects were significantly better than with the statin alone in each trial and in a pooled analysis. The safety profile of ezetimibe co-administered with a statin was similar to that of statin monotherapy and to that of placebo. For patients with primary hypercholesterolemia, co administration of ezetimibe and a statin offers a new treatment option to improve the overall lipid profile, and coadministration with a statin at a dose of 10 mg .day -1 permits a similar degree of LDL-C lowering as high-dose statins [19] [20] [21] [22] [23] [24] .
Special populations

Heterozygous familial hypercholesterolemia and other high-risk patients with refractory hypercholesterolemia
A randomized, double-blind, 14-week, response-based titration study was conducted to evaluate the LDL-Clowering efficacy of ezetimibe 10 mg added to atorvastatin 10 mg followed by response-based titration compared with atorvastatin titration alone [25, 26] . Following a 6 to 10 week washout and an open-label atorvastatin 10 mg .day -1 runin period of at least 4weeks, 621 patients with either documented CHD or at least two risk factors or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C was uncontrolled ( ≥ 3·4 mmol .l -1 ; 130 mg .dl -1 ) by the open-label atorvastatin, were randomized to receive ezetimibe 10 mg .day -1 or an additional 10 mg .day -1 of atorvastatin (double-blind) added to their open-label 10 mg of atorvastatin. The atorvastatin dose in each treatment group was doubled after 4 and/or 9weeks in patients whose LDL-C level was >2·6 mmol .l -1 (100 mg .dl -1 ; to a maximum of 80 mg in the monotherapy group and 40 mg in the co-administration group). The primary endpoint was the proportion of patients reaching a target LDL-C goal of ≤ 2·6 mmol .l -1 at 14 weeks. A key secondary endpoint was the percentage LDL-C reduction at 4weeks, when a direct comparison can be made between the addition of ezetimibe to the starting dose of atorvastatin versus doubling the dose of atorvastatin. This study examined particularly high-risk patients, given their cardiovascular risk factors or having the diagnosis of HeFH and the fact that the mean LDL-C while receiving atorvastatin 10 mg .day -1 was approximately 187 mg .dl -1 . After 14 weeks of treatment, significantly more patients in the ezetimibe group than in the atorvastatin monotherapy group reached LDL-C goal (22% versus 7%; P <0·01). At week 4, LDL-C was reduced 22·8% in patients receiving ezetimibe 10 mg plus atorvastatin 10 mg and 8.6% in patients receiving atorvastatin 20 mg ( P <0·01) [25] . Similar results were observed in the subgroup of patients with HeFH [n =362 (58·3%)]. Approximately four times as many patients reached LDL-C goal in the co-administration group than in the atorvastatin monotherapy group (17% versus 4%; P <0·01). Adding ezetimibe 10 mg to atorvastatin 10 mg also produced larger LDL-C reductions in HeFH patients at week 4 than doubling the atorvastatin dose to 20 mg (-23·6% versus -7·4%); P <0·01) [26] . Ezetimibe co-administered with atorvastatin was well tolerated and had a safety profile similar to atorvastatin alone. This study demonstrated that ezetimibe can facilitate LDL-C goal attainment even in high-risk, difficult-to-treat patients with CHD and HeFH.
Homozygous familial hypercholesterolemia
Homozygous familial hypercholesterolemia (HoFH), a rare disorder occurring in approximately 1 per 1,000,000 persons, is characterized by severely elevated LDL-C and extremely high risk for premature CHD. Despite aggressive use of diet therapy, statins, bile acid sequestrants, niacin, fibrates, or combination therapy, LDL-C levels remain high in most patients. Although LDL apheresis offers promise as a treatment for HoFH, it is time consuming, expensive, and not available to many patients [27, 28] .
Study design
In a double-blind, parallel-group study to evaluate the efficacy, safety, and tolerability of ezetimibe as an adjunct to diet and a statin (atorvastatin or simvastatin), with or without LDL apheresis, to treat patients with HoFH, 50 patients were randomized to receive statin 80 mg (n =17), ezetimibe 10 mg plus statin 40 mg (n =16), or ezetimibe 10 mg plus statin 80 mg (n =17) for 12 weeks. Prior to randomization, patients received open-label, nonrandomized atorvastatin or simvastatin 40 mg for 6 to 14 weeks and continued on the same statin during the randomized treatment phase; 36 received atorvastatin and 14 received simvastatin. Concomitant LDL apheresis was received by 8 statin monotherapy and 17 combination therapy patients [29] . The primary efficacy endpoint was the percentage change in the plasma concentration of directly measured LDL-C from baseline (while receiving open-label statin 40 mg) to final assessment. Secondary efficacy endpoints were the percentage change in plasma concentrations of other lipid and lipoprotein parameters, such as HDL-C, TG, apo A-I, and apo B, from baseline to final assessment. The primary analysis compared patients receiving statin 80 mg with patients receiving ezetimibe 10 mg plus statin 40 mg or ezetimibe 10 mg plus statin 80 mg [29] .
Efficacy results
From baseline to final assessment, treatment with ezetimibe 10 mg plus a statin (either 40 mg or 80 mg) produced a greater reduction in directly measured LDL-C than did statin 80 mg monotherapy (20·7% vs 6·7%, P =0·007). When the ezetimibe 10 mg plus statin 80 mg group was compared with the statin 80 mg group, the LDL-C reduction between the higher doses was even more pronounced (27·5% vs 7·0%, P =0.0001) (Fig. 5) . The LDL-Clowering effect of ezetimibe 10 mg plus statin 40 mg or 80 mg was observed as early as 2weeks after the addition of ezetimibe and persisted throughout the 12-week randomized treatment phase. Similar reductions in LDL-C were observed in subjects receiving and not receiving LDL apheresis. Ezetimibe produced similar LDL-C-lowering results whether it was combined with atorvastatin or simvastatin. However, i n this relatively small study, differences in changes in mean HDL-C, TG, and apo A-I concentrations were not statistically significant [29] .
Safety results
There were no clinically meaningful differences in the incidence of AEs between patients receiving ezetimibe plus statin and patients receiving statin monotherapy. Only two patients discontinued therapy because of an AE, one in the ezetimibe plus statin 40 mg group who had epigastric pain and ischemic chest pain and one in the ezetimibe plus statin 80 mg group who discontinued 1week after randomization when it was noted that his prerandomization ALT and AST levels were >3×ULN, which should have excluded him from the study [29] .
Analyses of additional measures of safety (laboratory results, ECG parameters, and cardiopulmonary examinations) indicated no differences between monotherapy and combination therapy. Asymptomatic single transient increases in serum ALT and/or AST ≥ 3×ULN occurred in one monotherapy and one combination therapy patient. There were no clinically significant increases in CK concentrations or episodes of myopathy or rhabdomyolysis [29] .
Implications
The additional reduction in LDL-C when ezetimibe was coadministered with a moderate (40 mg) or maximal (80 mg) dose of either of the two most widely used statins is particularly important given the fact that other pharmacologic therapies for HoFH, including high-dose statin monotherapy, h ave met with limited success [27] . While a major lipid-lowering mechanism of action of statins is up-regulation of the LDL receptor, which is absent or poorly functional in patients with HoFH, the primary lipidlowering mechanism of ezetimibe, inhibition of cholesterol absorption at the intestinal brush border, appears to be largely unaffected by the pathophysiology of HoFH [29] .
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Homozygous sitosterolemia
Sitosterolemia is a rare inherited disorder that causes increased absorption and decreased excretion of plant sterols such as sitosterol and campesterol, leading to markedly elevated levels of plant sterols in plasma and tissue that can lead to premature atherosclerosis. In patients with homozygous sitosterolemia, the disorder is caused by a recessive gene mutation in ABCG5 or ABCG8 [30, 31] .
In a double-blind study conducted in 37 patients with homozygous sitosterolemia, participants were randomized in a 4:1 ratio to ezetimibe 10 mg once daily (n =30), or to placebo (n =7). After 8weeks of treatment, plasma concentrations of sitosterol decreased from baseline by a mean of 21% in ezetimibe-treated patients ( P <0·001) and increased by 4% in placebo patients, for a betweentreatment difference of 25% ( P <0·0001). The reduction from baseline was progressively greater at each subsequent biweekly visit, and reductions were similar across sex and age categories and regardless of whether patients were taking bile acid sequestrants and/or statins [2] . Similar results were seen for plasma concentrations of campesterol, which was reduced by a mean of 24·3% in ezetimibe-treated patients from baseline to 8weeks, compared with a mean increase of 3·2% in placebo patients, for a betweentreatment difference of 27·5% [2] .
LDL-C concentrations declined with ezetimibe treatment, but the difference between treatment groups was not significant. Many patients had low or low-normal LDL-C levels at baseline. Apo B and total sterol concentrations decreased with ezetimibe treatment [2] .
In these patients with homozygous sitosterolemia, shortterm treatment with ezetimibe provided significant, progressive reductions in plant sterol concentrations. Ezetimibe was safe and well tolerated in this patient group. The possible clinical benefit of longer-term treatment with ezetimibe on concentrations of plant sterols needs to be examined in subsequent trials [2] .
Future areas for research: concomitant use with lipid-modifying agents besides statins
Other lipid-modifying agents, i ncluding new classes of agents, may also hold promise for use in conjunction with ezetimibe. Peroxisome proliferator-activated receptor (PPAR)-α agonists, such as fenofibrate, decrease LDL-C and TG and increase HDL-C. In a small, randomized, placebo-controlled trial evaluating the lipid-altering efficacy of ezetimibe co-administered with fenofibrate, 32 patients with primary hypercholesterolemia (baseline LDL-C ≥ 130 mg .dl -1 ), were randomized to one of four treatments: ezetimibe 10 mg, fenofibrate 200 mg, ezetimibe 10 mg plus fenofibrate 200 mg, or placebo for 14 days while in a hospital setting [32, 33] . The co-administration of ezetimibe 10 mg and fenofibrate 200 mg caused a significant ( P ≤ 0·03) reduction in LDL-C levels (36·3%) compared with placebo (10·1%), fenofibrate alone (22·3%), or ezetimibe alone (13·5%). HDL-C decreased in all treatment groups, presumably because of reduced activity in the hospital; however, the ezetimibe plus fenofibrate group had the least decrease (2·0%). This group also had the greatest decrease in TG levels (32·4%) [32] . In addition, ezetimibe alone and ezetimibe plus fenofibrate both caused significantly greater reductions in apo C-III compared with placebo ( P ≤ 0·01). Ezetimibe plus fenofibrate also caused a significant reduction ( P ≤ 0·05) in small, dense LDL (LDL III) compared with either drug alone or placebo [33] . Ezetimibe plus fenofibrate was well tolerated, and AE profiles were similar among the treatment groups. Though promising, these results will need to be confirmed in a larger, longer trial. PPAR-γ agonists such as rosiglitazone and pioglitazone improve insulin sensitivity, reduce TG, and raise HDL-C but are associated with increased LDL-C. Future studies will need to examine the combination of ezetimibe and PPAR-γ agonists.
The combination of nicotinic acid with a low dose of simvastatin has shown impressive b enefits in an angiographic trial [34] , and a new combination agent with lovastatin and once-daily niacin is now available. Ezetimibe and niacin with or without a statin may be another option for aggressive modification of multiple lipid parameters. Additional data are needed on co-administration of ezetimibe and bile acid resins; a small phase I study suggests that there may be a drug-drug interaction with cholestyramine (data on file) with a reduction in ezetimibe plasma levels, but the more commonly used colesevelam, which has fewer drug interactions, has not been studied with ezetimibe.
Conclusion
Ezetimibe, a new once-daily inhibitor of cholesterol absorption, has been studied in monotherapy, in combination therapy with statins, in combination therapy with fenofibrate, and in difficult-to-treat populations such as patients with familial hypercholesterolemia or sitosterolemia. The data show that the agent is largely devoid of drug interactions and does not affect the cytochrome P450 system. The data from phase II and phase III studies are consistent in showing benefits on reducing LDL-C, TG, and total cholesterol, and raising HDL-C. In the monotherapy studies, safety has been similar to placebo, and in combination therapy with statins, safety has been comparable with statin monotherapy. In summary, ezetimibe has been shown to be an effective and safe new option for treating hypercholesterolemia even in homozygous and heterozygous familial hypercholesterolemia and homozygous sitosterolemia.
